Clinical Trial Update: Optimized Dual CD33/CLL1 CAR T Cells in Subjects With Refractory or Relapsed Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating dual CD33/CLL1 CAR T cells for patients with refractory or relapsed Acute Myeloid Leukemia has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Dual CD33/CLL1 CAR T cells

Snippet

Sponsor: Beijing Boren Hospital | Conditions: Acute Myeloid Leukemia | Phase 1 | Status: WITHDRAWN